Thermo Fisher Scientific Inc (TMO)
OvervaluedFundamental
61
Price
$673.82
Market Cap
$256.61B
Part 1 · What the company is worth
Overview
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$46.34B
Trailing 12 months (through 6/27/2026)
Net Income
$6.97B
Trailing 12 months (through 6/27/2026)
Free Cash Flow
$6.29B
Total Equity
$53.41B
Total Liabilities
$56.93B
Current Ratio
1.55
Interest Coverage
5.46
Debt/EBITDA
3.62
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$458.73
Current Price
$673.82
Margin of Safety
-46.9%
Fair Value Range
$298.17 - $619.28
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
36.25
ROE
12.6%
P/B Ratio
4.73
P/FCF
34.05
Gross Margin
-
ROIC
6.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
6.6%
WACC
8.3%
ROIC − WACC
-1.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (18)
- EPS shows upward trend
- EPS CAGR 13.95%
- Price CAGR 16.92%
- ROIC 6.6%
- Debt/equity ratio
- Operating margin 17.6%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- ROE 13.3%
- Revenue growth 5Y 6.7%
- Earnings surprise, average 2.9%
- Earnings quality (operating cash flow / net income) 1.29
- Share dilution -1.4%
- Piotroski F-Score 5/9
Failed (7)
- P/FCF 34.05
- P/B ratio 4.73
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG ratio 17.60
- Net margin trend 15.0% vs 15.2%
Unavailable (2)
- Gross margin –
- Dividend payout –
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Marc N. Casper | Chairman & CEO | 57 |
| Mr. Gianluca Pettiti | President, COO & President of Products and Technologies | 46 |
| Mr. James R. Meyer | Senior VP & CFO | 46 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 45 |
| Mr. Ryan J. Snyder | Senior VP & Chief Information Officer | - |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer | - |
| Mr. Rafael Tejada | Vice President of Investor Relations | - |
| Mr. Thomas Bailey Shropshire Jr. | Senior VP and General Counsel | - |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | - |
| Mr. Alan J. Malus | Senior Vice President of Strategy & Corporate Development | 65 |
Audit Risk
2
Board Risk
7
Compensation Risk
10
Shareholder Rights Risk
1
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-26
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-31
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-21
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much TMO moves, measured on its daily prices.
More volatile than 31% of the tracked stocks (90-day volatility).
- Volatility 30d
- 28.0%
- Volatility 90d
- 28.9%
- Beta vs S&P 500 (1y)
- 0.56Correlation 0.24
- Max drawdown (12m)
- -31.5%
- ATR (14d, % of price)
- 3.05%
Earnings reactions
How TMO moved around its past quarterly results.
Next earnings release
No upcoming release on the calendar.
What usually happens
- Over the last 12 releases the stock moved a median of 3.3% the next day, up or down.
- Next-day moves: up 7, down 5 (out of 12).
- Of the 5 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | Before the open | 6.40 | 6.68 | +4.3% | -3.3% | +1.0% | n/a |
| Jul 23, 2026 | Before the open | 5.77 | 6.03 | +4.5% | +9.0% | +8.7% | +9.5% |
| Apr 23, 2026 | Before the open | 5.29 | 5.44 | +2.8% | -8.0% | -9.2% | -9.3% |
| Jan 29, 2026 | Before the open | 6.51 | 6.57 | +0.9% | -3.7% | -2.6% | -7.0% |
| Oct 22, 2025 | Before the open | 5.55 | 5.79 | +4.4% | -0.4% | +1.7% | -0.1% |
| Jul 23, 2025 | Before the open | n/a | n/a | n/a | +10.7% | +9.1% | +12.8% |
| Apr 23, 2025 | Before the open | n/a | n/a | n/a | +5.0% | -0.7% | -1.7% |
| Jan 30, 2025 | Before the open | n/a | n/a | n/a | +3.9% | +6.8% | +2.5% |
| Oct 23, 2024 | Before the open | n/a | n/a | n/a | -2.0% | -1.7% | -6.6% |
| Jul 24, 2024 | Before the open | n/a | n/a | n/a | +0.1% | +4.1% | +11.4% |
| Apr 24, 2024 | Before the open | n/a | n/a | n/a | +0.6% | +0.5% | -1.0% |
| Jan 31, 2024 | Before the open | n/a | n/a | n/a | -0.7% | -5.0% | -1.2% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on TMO and what the price did next.
- 10/21/2026PositiveThermo Fisher, terzo trimestre sopra le attese con utile in crescita a doppia cifra
- +1 day
- +0.4%
- +3 days
- pending
- 10/19/2026PositiveDue titoli pronti a beneficiare della rotazione fuori dall'IA
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 5/25/2026PositiveIf You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today
- +1 day
- -0.7%
- +3 days
- +7.5%
- 3/12/2026PositiveHere's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
- +1 day
- -1.9%
- +3 days
- -1.4%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for TMO.
- 3d agoPOSITIVEThermo Fisher, terzo trimestre sopra le attese con utile in crescita a doppia cifra
Thermo Fisher Scientific, a US-based life sciences and research services company, reported a strong third quarter of 2026, exceeding expectations with double-digit profit growth. While specific revenue figures and profit margins are pending full disclosure, the company's performance indicates robust demand for its products and services. This positive earnings trend suggests effective operational management and successful market penetration, potentially leading to increased investor confidence and upward price adjustments for the stock.
- 5d agoPOSITIVEDue titoli pronti a beneficiare della rotazione fuori dall'IA
As investors rotate out of artificial intelligence (AI) stocks, two healthcare equipment providers, Thermo Fisher Scientific (TMO) and Waters (WAT), are identified as prime beneficiaries. Josh Brown highlights these companies, noting that their improving business activities are attracting buyers while tech stocks face pressure. The opportunity lies in exposure to diverse earnings drivers, despite both stocks having already seen significant rebounds. Waters, in particular, offers exposure to laboratory equipment, consumables, and diagnostic tools, with a recent integration of BD's Biosciences and Diagnostic Solutions businesses further expanding its reach. This strategic positioning suggests potential for continued growth as market focus shifts.
- 5/25/2026POSITIVEIf You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today
An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.
- 3/12/2026POSITIVEHere's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.
- 3/2/2026NEUTRALHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.